Form SC 13G/A REGENERON PHARMACEUTICAL Filed by: BlackRock Inc.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Roth Affirms Regeneron (REGN) at 'Buy' Following Q4 Results; Sees Opportunity in Shares on Pullback
February 10, 2016 11:53 AM ESTRoth Capital reaffirmed Regeneron (Nasdaq: REGN) at Buy with a price target of $555 after the company reported Q4 EPS of $2.83 and revenue of $1.1 billion, versus consensus estimates calling for EPS of $3.31 and revenue of $1.17 billion, this week.
Analyst Joseph Pantginis commented: REGN's shares have not been immune to the enhanced market turbulence surrounding... More
